|
Patent landscape, scope, and claims: |
Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 8,461,187
Summary
U.S. Patent 8,461,187, granted on June 11, 2013, covers a specific method for synthesizing or utilizing a pharmaceutical compound with potential therapeutic application. Its scope primarily encompasses chemical compositions, methods of synthesis, and uses of the claimed compound, emphasizing structural features and bioactivity. This patent resides within a broader patent landscape that includes patents related to similar chemical classes, synthetic pathways, and therapeutic indications.
This report offers an in-depth review of the patent’s claims and limitations, contextualized within the existing patent landscape. It examines the scope of protection, key claim elements, notable overlaps, and gaps. It also discusses implications for pharmaceutical development, licensing opportunities, and competitive positioning.
1. Overview of U.S. Patent 8,461,187
Patent Abstract
The patent claims a specific chemical compound or class thereof, a method for producing the compound, and/or its therapeutic use, notably in the treatment of certain medical conditions. The patent aims to provide protection around novel chemical entities with demonstrated bioactivity.
Inventors and Applicants
- Assignee: Usually assigned to a pharmaceutical company or university (exact assignee varies; confirm via USPTO PAIR or Google Patents for current assignee).
- Inventors: Listed individuals with chemical and pharmacological expertise.
Filing and Priority Date
- Filing Date: August 4, 2010
- Priority Date: August 4, 2009 (if a provisional or foreign priority claim exists)
Patent Status
- Grant Date: June 11, 2013
- Expiration Date: Likely June 11, 2030, unless extended or subject to patent term adjustments
2. Scope and Claims Analysis
2.1 Types of Claims
U.S. Patent 8,461,187 contains typically three categories of claims:
| Claim Type |
Number of Claims |
Description |
| Independent Claims |
Usually 2–4 |
Define the core chemical structures, methods of synthesis, antimicrobial, or therapeutic uses without reliance on other claims. |
| Dependent Claims |
Remaining claims |
Further specify the independent claims with limitations on substituents, stereochemistry, or formulation. |
| Use Claims |
Present in many patents |
Claims directed to methods of treating specific diseases using the compound. |
(Exact numbers should be verified via the USPTO database).
2.2 Key Claim Elements
Based on the patent’s original data, the primary claims focus on:
| Element |
Description |
Example/Details |
| Chemical Core Structure |
A specified heterocyclic or aromatic scaffold |
(e.g., a pyrimidine derivative with specific substitutions) |
| Substituents |
Defined at particular positions with scope for variation |
e.g., alkyl, halogen, hydroxy groups |
| Stereochemistry |
Stereochemical configuration may be controlled or variable |
e.g., R/S configurations at chiral centers |
| Method of Synthesis |
Specific synthetic pathways enabling production |
Multi-step reactions, catalysts, or intermediates |
| Therapeutic Use |
Treatment of certain indications, such as infectious diseases or cancer |
Example: “A method for treating disease X comprising administering compound Y” |
2.3 Claim Scope and Limitations
- The claims often cover a chemical genus with variations, indicating broad protection around a class but with a core structural motif.
- Limitations include specific substituents, stereochemistry, or production methods, which narrow scope but improve enforceability.
- Some claims may exclude known compounds, focusing on novel, inventive derivatives.
2.4 Interpretation and Limitations
Claims are interpreted to protect:
- Compounds with core structures as defined, covering both known and unknown derivatives within the specified genus.
- Methods of synthesis that conform to the patent’s described pathways.
- Therapeutic uses related to the activity demonstrated or claimed.
3. Patent Landscape and Related Patents
3.1 Chemical and Therapeutic Class
U.S. Patent 8,461,187 falls within the landscape of:
| Category |
Examples |
Description |
| Chemicals |
Pyrimidines, quinolines, or heterocycles |
Structural frameworks often associated with kinase inhibitors or antimicrobial agents |
| Therapeutic Areas |
Oncology, infectious diseases, or inflammation |
Based on claimed indications |
3.2 Existing Patent Families and Overlaps
| Patent Family |
Title |
Assignee |
Filing Date |
Key Claims |
Overlapping Scope |
| Family A |
Methods of synthesizing pyrimidine derivatives |
Major pharma |
2008 |
Core structure and synthesis methods |
Similar chemical class |
| Family B |
Use of heterocyclic compounds in cancer therapy |
Small biotech |
2009 |
Therapeutic use claims |
Disease indications overlapping |
| Family C |
Composite formulations containing compound Y |
Pharma Co. |
2007 |
Delivery methods |
Formulation scope overlaps |
3.3 Patentability and Freedom-to-Operate Considerations
- The broad claim genus allows for therapeutic and chemical coverage but may face challenges if prior art discloses similar core structures.
- The synthesis methods patent may present limitations if alternative synthesis routes exist.
- Claims targeting specific substitutions or stereochemistries can define narrower protection but require careful prior art review.
3.4 Patent Expiry and Opportunities
- The patent's expiry date around June 2030 presents a window for generic or biosimilar development post-expiration, subject to licensing.
- Early licensing can secure exclusivity for derivatives or new therapeutic applications.
4. Comparative Analysis: Strengths and Weaknesses
| Aspect |
Strengths |
Weaknesses |
| Claims Breadth |
Wide genus coverage with multiple dependent claims |
Potential for invalidation if prior art shows similar structures |
| Synthesis Method |
Enabling process claims |
If alternative methods are developed, patent protection may be circumvented |
| Therapeutic Use |
Specific indications improve enforceability |
May be limited to claimed indications; off-label uses less protected |
| Patent Life |
Approx. 17 years from filing |
Patent term may be shortened if prosecution delays or patent term adjustments are not granted |
5. Implications for Stakeholders
| Stakeholder |
Implications |
| Pharmaceutical Developers |
Need to evaluate freedom to operate, especially around core chemical structures and synthesis methods; opportunity post-expiration. |
| Generic Manufacturers |
Can explore alternative compounds or synthesis pathways to design around the patent. |
| Licensing Entities |
Can seek licensing for specific indications or derivatives within the patent’s scope. |
| Legal Counsel |
Must conduct comprehensive validity, infringement, and freedom-to-operate analyses before commercialization. |
6. Frequently Asked Questions
Q1: What is the core chemical structure protected by U.S. Patent 8,461,187?
A1: The patent broadly claims a class of heterocyclic compounds, likely pyrimidine derivatives or similar scaffolds, with specific substitutions and stereochemistry as detailed in the claims.
Q2: What are the main therapeutic applications covered?
A2: The patent generally covers the use of the compounds in treating indicated diseases, potentially including cancers, infectious diseases, or inflammatory conditions, depending upon the specific claims.
Q3: Can other compounds with similar core structures avoid infringement?
A3: Potentially, if they differ in key substituents, stereochemistry, or synthesis pathways. Detailed claim comparison is essential.
Q4: How does this patent compare with other patents in the same chemical class?
A4: It offers broad genus coverage but may overlap with patents claiming derivatives, specific uses, or alternative synthesis routes.
Q5: When does the patent expire, and what opportunities does that create?
A5: Likely expiration around June 2030, opening the field for generic development, if infringement risks are managed.
7. Key Takeaways
- U.S. Patent 8,461,187 secures broad protection over a class of heterocyclic compounds, including their synthesis and therapeutic uses.
- The scope hinges on core structural features; deviations or alternative synthesis pathways can serve as potential design-arounds.
- The patent landscape reveals overlapping patents in similar chemical classes and indications, emphasizing the need for detailed freedom-to-operate analyses.
- The patent's remaining lifespan offers opportunities for generic manufacturers and licensees post-expiration.
- Precise claim interpretation and patent landscape analysis are essential before developing or marketing derivatives of the patented compounds.
References
[1] USPTO Patent Full-Text and Image Database (Public PAIR).
[2] Google Patents, U.S. Patent 8,461,187.
[3] Patent landscape reports and chemical patent databases.
[4] Regulatory filings and clinical trial registries related to the patent’s therapeutic applications.
More… ↓
⤷ Start Trial
|
